Rapid clinically meaningful response seen, which was maintained for 48 weeks for moderate-to-severe hidradenitis suppurativa<\/p>\n<\/h3>\n
By Elana Gotkine HealthDay Reporter<\/b><\/p>\n
<\/b><\/p>\n
THURSDAY, May 30, 2024 (HealthDay News) — Bimekizumab is well tolerated and produces clinically meaningful responses in patients with hidradenitis suppurativa, according to a study published online May 22 in The Lancet<\/em>.<\/p>\n Alexa B. Kimball, M.D., from the Beth Israel Deaconess Medical Center and Harvard Medical School in Boston, and colleagues examined the efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa in two identically designed, 48-week randomized, placebo-controlled trials (BE HEARD I and II [505 and 509 patients, respectively]). Patients (aged 18 years and older) were randomly assigned to receive subcutaneous bimekizumab 320 mg every two weeks; bimekizumab 320 mg every two weeks to week 16, then every four weeks to week 48; bimekizumab 320 mg every four weeks to week 48; or placebo to week 16, then bimekizumab 320 mg every two weeks in a 2:2:2:1 ratio. The primary outcome was a hidradenitis suppurativa clinical response of at least 50 percent (HiSCR50) at week 16.<\/p>\n The researchers found that using modified nonresponder imputation, the primary outcome at week 16 was met in the group who received bimekizumab every two weeks; in both trials, higher responder rates were seen with bimekizumab versus placebo (odds ratios, 2.23 and 2.29, respectively, in BE HEARD I and II). HiSCR50 was also met in the group administered bimekizumab every four weeks in BE HEARD II (odds ratio, 2.42). The investigators observed a maintenance or increase in responses to week 48. In 8 and 5 percent of patients in BE HEARD I and BE HEARD II, respectively, serious treatment-emergent adverse events were reported.<\/p>\n “These data support the use of bimekizumab as a promising new therapeutic option for patients with moderate-to-severe hidradenitis suppurativa,” the authors write.<\/p>\n Several authors disclosed ties to biopharmaceutical companies, including UCB Pharma, which manufactures bimekizumab and funded the trial.<\/p>\n Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n Editorial (subscription or payment may be required)<\/a><\/p>\n <\/i><\/p>\n